- Headquarters: Lake Bluff, Illinois
- Market Cap 202.3 billion USD (Aug. 21)
- Dividend Yield 4.54% (Aug. 21)
- AbbVie’s flagship therapy, Humira, a medicine used to treat a slew of conditions from arthritis to psoriasis to Crohn’s disease and ulcerative colitis, is the bestselling drug in the world, bringing in nearly $20 billion in global sales annually.
- Another specialty drug, ibrutinib, costs US$116,600 to $155,400 a year wholesale in the United States.
- Acquired Allergan (AGN), the maker of the highly popular cosmetic product Botox.. (June 2019)
- abbvie.com
AbbVie's portfolio of products includes a diversified therapy that address some of the world's most complex and serious diseases. AbbVie's top 3 products are HUMIRA®, IMBRUVICA® and MAVYRET™; contributes together USD 27 billion which is 80% of total revenue.
Annual revenue in USD billions
The firm's largest single product is multi-purpose drug Humira, which represents approximately 60% of the company’s total revenue
HUMIRA® (adalimumab) is an expensive medication used to treat autoimmune diseases such as rheumatoid and psoriatic
arthritis. It is also used to treat ankylosing spondylitis, Crohn's
disease, and ulcerative colitis. It is administered as a subcutaneous injection.
Currently It is approved in the United States, Canada and Mexico and in the European Union. HUMIRA® is also approved in Japan for the treatment of intestinal Behçet's disease. FY 2018 revenue from HUMIRA® was USD 19.93 billion.
There are currently no generic alternatives to Humira as it is a biologic medication. There are concerns however — the drug has already lost patent
exclusivity in Europe and will lose exclusivity in the U.S. in 2023. 
AbbVie eyes the end of patent protection for Humira, the world's best-selling drug.
MAVYRET™ (glecaprevir and pibrentasvir) an expensive drug used to treat hepatitis C. Global MAVYRET sales increased by more than 100% in 2018 as a result of market share gains following the FDA and EMA approvals of MAVYRET in the second half of 2017 as well as further geographic expansion in 2018. FY 2018 revenue from MAVYRET™ was USD 3.59 billion.
Mavyret was approved by the U.S. Food and Drug Administration on August 3, 2017 for the treatment of chronic hepatitis C infection.
AbbVie acquired Pharmacyclics in March 2015
IMBRUVICA® (ibrutinib) is an oral, once-daily therapy that targets proteins in cancer cells and stops the cancer cells from growing. It was one of the first medicines to receive a United States Food and Drug Administration (FDA) approval after being granted a Breakthrough Therapy Designation and is one of the few therapies to receive four separate designations. IMBRUVICA® currently is approved for the treatment of adult patients with diseases such as Chronic lymphocytic leukemia, Mantle cell lymphoma, Waldenström’s macroglobulinemia, Marginal zone lymphoma (MZL) and Chronic graft versus host disease (cGVHD). FY 2018 worldwide revenue from IMBRUVICA® was USD 3.43 billion.
monthly chart
Pharmaceutical drugs
Humira (adalimumab)
Imbruvica (ibrutinib)
Venclexta (venetoclax)
Zinbryta (daclizumab)
Kaletra (lopinavir)
Norvir (ritonavir)
Mavyret/Maviret (glecaprevir/pibrentasvir)
Skyrizi (risankizumab)
AbbVie's pipeline
No comments:
Post a Comment